Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ULTRA Hybrid FVRCP
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**ULTRA Hybrid FVRCP** is a non-adjuvanted, reduced-volume (0.5 mL) feline core vaccine developed by Elanco for preventing three major viral diseases in cats: feline viral rhinotracheitis (FVR, caused by feline herpesvirus FHV-1), feline calicivirus (FCV), and feline panleukopenia (FPV). It combines an exclusive inactivated dual-strain calicivirus (targeting both traditional and novel strains for broader protection) with modified-live components for panleukopenia and feline herpesvirus, leveraging PureFil™ Technology to minimize extraneous proteins and cellular debris for reduced discomfort and reactions. Administered subcutaneously, it offers effective immunity with a more comfortable injection experience compared to standard 1 mL adjuvanted vaccines, and is part of Elanco's ULTRA line of purified feline vaccines.[1][4][7]
- Brand names
- ULTRA Hybrid FVRCPTruFel Ultra HC2P Hybrid
- Other names
- Ultra Hybrid FVRCP
Beyond the preview
Go deeper on ULTRA Hybrid FVRCP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ULTRA Hybrid FVRCP.